fulvestrant has been researched along with Cells, Neoplasm Circulating in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Aftimos, P; Arlt, H; Bardia, A; Bidard, FC; Bihani, T; Binaschi, M; Burr, R; Chirn, B; Cortés, J; Dubash, TD; Fiascarelli, A; Habboubi, N; Haber, DA; Iafrate, AJ; Kaklamani, VG; LiCausi, JA; Maheswaran, S; Patel, H; Rai, S; Reeves, BA; Scartoni, S; Toner, M; Wittner, BS | 1 |
| Brown, M; De Angelis, C; Jeselsohn, R; Schiff, R | 1 |
| Aung, K; Brown, ME; Cannell, EM; Chianese, DA; Connelly, MC; Darga, EP; Hayes, DF; Henry, NL; Kidwell, KM; Larios, JM; Muñiz, MC; Paoletti, C; Rae, JM; Schott, AF; Thomas, DG; Tokudome, N | 1 |
| Chia, SK; McLeod, D; Paterson, A; Pritchard, KI; Provencher, L; Rayson, D; Simmons, C | 1 |
| DiLeonardo, M; Gibbons, G; Resnik, KS | 1 |
1 review(s) available for fulvestrant and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mutation; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prognosis; Tamoxifen | 2017 |
5 other study(ies) available for fulvestrant and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Models, Animal; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplastic Cells, Circulating; Receptors, Estrogen | 2023 |
Targeting Mutant AKT in Cancer.
Topics: Clinical Trials, Phase I as Topic; Drug Synergism; Estradiol; Fulvestrant; Humans; Mutation; Neoplasms; Neoplastic Cells, Circulating; Precision Medicine; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.
Topics: Aromatase Inhibitors; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Humans; Neoplastic Cells, Circulating; Receptors, Estrogen; Treatment Outcome | 2016 |
Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Circulating Tumor DNA; Disease-Free Survival; Estradiol; Female; Fulvestrant; Humans; Letrozole; Mutation; Neoplastic Cells, Circulating; Nitriles; Nuclear Proteins; Piperazines; Postmenopause; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Transcription Factors; Triazoles | 2017 |
Clinically occult cutaneous metastases.
Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Capecitabine; Carcinoma; Carcinoma, Basal Cell; Carcinoma, Lobular; Carcinoma, Signet Ring Cell; Deoxycytidine; Estradiol; Facial Neoplasms; Female; Fluorouracil; Fulvestrant; Humans; Incidental Findings; Letrozole; Mastectomy, Radical; Megestrol Acetate; Melanoma; Neoplasms, Second Primary; Neoplastic Cells, Circulating; Nitriles; Selective Estrogen Receptor Modulators; Skin Neoplasms; Tamoxifen; Triazoles; Wound Healing | 2006 |